Long-term cardiac outcomes of treating chronic chagas disease with benznidazole versus no treatment: A nonrandomized trial

Annals of Internal Medicine

Volumn 144, Issue 10, 2006, Pages 724-734

  Viotti, Rodolfo ^a,b   Vigliano, Carlos ^a,b   Lococo, Bruno ^a,b   Bertocchi, Graciela ^a,b   Petti, Marcos ^a,b   Alvarez, María Gabriela ^a,b   Postan, Miriam ^a,b   Armenti, Alejandro ^a,b  

^a Hospital Interzonal General de Agudos Eva Peronquot   (Argentina)

^b NONE   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; BENZNIDAZOLE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE; PROTOZOON ANTIBODY;

ADULT; ARTICLE; CHAGAS DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEART FUNCTION; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PRURITUS; SKIN ALLERGY; TREATMENT OUTCOME; ANIMAL; BLOOD; CHRONIC DISEASE; DISEASE COURSE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; IMMUNOLOGY; MALE; MIDDLE AGED; PARASITOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TRYPANOSOMA CRUZI;

ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; CHRONIC DISEASE; DISEASE PROGRESSION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 33646847271     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-144-10-200605160-00006     Document Type: Article

References (47)

1. Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000;343:1388-98.
2. World Health Organization. Control of Chagas disease. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 2002;905:1-109.
3. Dias E, Laranja FS, Miranda A, Nobrega G. Chagas disease. A clinical, epidemiologic and pathologic study. Circulation. 1956;14:1035-60.
4. Hagar JM, Rahimtoola SH. Chagas' heart disease. Curr Probl Cardiol. 1995;20:825-924.
5. Manzullo EC, Chuit R. Risk of death due to chronic chagasic cardiopathy. Mem Inst Oswaldo Cruz. 1999;94 Suppl 1:317-20.
6. Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL. Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg. 1993;48:348-57.
7. Higuchi ML, De Brito T, Reis MM, Barbosa A, Bellotti G, Pereira-Barreto AC, et al. Correlation between Trypanosoma cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovasc Pathol. 1993;2:101-6.
8. Bellotti G, Bocchi EA, de Moraes AV, Higuchi ML, Barbero-Marcial M, Sosa E, et al. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease. Am Heart J. 1996;131:301-7.
9. Brandariz S, Schijman A, Vigliano C, Arteman P, Viotti R, Beldjord C, et al. Detection of parasite DNA in Chagas' heart disease [Letter]. Lancet. 1995;346:1370-1.
10. Machado CR, Camargos ER, Guerra LB, Moreira MC. Cardiac autonomic denervation in congestive heart failure: comparison of Chagas' heart disease with other dilated cardiomyopathy. Hum Pathol. 2000;31:3-10.
11. Kierszenbaum F. Chagas' disease and the autoimmunity hypothesis. Clin Microbiol Rev. 1999;12:210-23.
12. Cançado JR. Tratamento específico. In: Cançado JR, Chuster M, eds. Cardiopatía Chagásica. Belo Horizonte, Brazil: Fundaçao Carlos Chagas; 1985:327-55.
13. Cançado JR. Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz. 1999;94 Suppl 1:331-5.
14. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994;127:151-62.
15. Fabbro De Suasnábar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo. 2000;42:99-109.
16. Gallerano RR, Sosa RR. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy]. Rev Fac Cien Med Univ Nac Cordoba. 2000;57:135-62.
17. Cancado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo. 2002;44:29-37.
18. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg. 1998;59:526-9.
19. de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348:1407-13.
20. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. [Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy]. Arq Bras Cardiol. 1985;45:249-56.
21. Barrett PA, Peter CT, Swan HJ, Singh BN, Mandel WJ. The frequency and prognostic significance of electrocardiographic abnormalities in clinically normal individuals. Prog Cardiovasc Dis. 1981;23:299-319.
22. Feigenbaum H. Echocardiography. 5th ed. Philadelphia: Lea & Febiger; 1994:68-133.
23. Maguire JH, Mott KE, Souza JA, Almeida EC, Ramos NB, Guimarães AC. Electrocardiographic classification and abbreviated lead system for population-based studies of Chagas' disease. Bull Pan Am Health Organ. 1982;16:47-58.
24. Steiner RM, Levin DC. Radiology of the heart. In: Braunwald E, ed. Heart Disease. 4th ed. Philadelphia: WB Saunders; 1992:204-34.
25. Freilij H, Storino R. Diagnóstico de laboratorio. In: Storino R, Milei J, eds. Enfermedad de Chagas. Buenos Aires: Mosby Doyma; 1994:343-57.
26. Voller A, Draper C, Bidwell DE, Bartlett A. Microplate enzyme-linked immunosorbent assay for chagas' disease. Lancet. 1975;1:426-8.
27. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118:201-10.
28. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002;136:349-57.
29. Apt W, Arribada A, Zulantay I, Sanchez G, Vargas SL, Rodriguez J. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. Ann Trop Med Parasitol. 2003;97:23-9.
30. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simões-Barbosa A, Tinoco DL, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg. 2000;63:111-8.
31. Viotti RJ, Vigliano C, Laucella S, Lococo B, Petti M, Bertocchi G, et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart. 2004;90:655-60.
32. Espinosa RA, Pericchi LR, Carrasco HA, Escalante A, Martínez O, González R. Prognostic indicators of chronic chagasic cardiopathy. Int J Cardiol. 1991;30:195-202.
33. Bestetti RB, Dalbo CM, Freitas OC, Teno LA, Castilho OT, Oliveira JS. Noninvasive predictors of mortality for patients with Chagas' heart disease: a multivariate stepwise logistic regression study. Cardiology. 1994;84:261-7.
34. Rodriguez-Salas LA, Klein E, Acquatella H, Catalioti F, Davalos VV, Gomez-Mancebo JR, et al. Echocardiographic and clinical predictors of mortality in chronic Chagas' disease. Echocardiography. 1998;15:271-278.
35. Dias JC. Historia natural da Doença de Chagas. Arq Bras Cardiol. 1995;65:359-66.
36. Maguire JH, Hoff R, Sherlock I, Guimarães AC, Sleigh AC, Ramos NB, et al. Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation. 1987;75:1140-5.
37. Storino R, Milei J. Evolución natural y estudios longitudinales. In: Storino R, Milei J, eds. Enfermedad de Chagas. Buenos Aires: Mosby Doyma; 1994:599.
38. Rosenbaum MB. Chagasic cardiomyopathy. Prog Cardiovasc Dis. 1964;7:199-225.
39. Andrade ZA, Andrade SG, Oliveira GB, Alonso DR. Histopathology of the conducting tissue of the heart in Chagas' myocarditis. Am Heart J. 1978;95:316-24.
40. Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA. [Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina]. Rev Soc Bras Med Trop. 2004;37:365-75.
41. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis. 1999;180:480-6.
42. Schijman AG, Vigliano CA, Viotti RJ, Burgos JM, Brandariz S, Lococo BE, et al. Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic chagas heart disease. Am J Trop Med Hyg. 2004;70:210-20.
43. Francolino SS, Antunes AF, Talice R, Rosa R, Selanikio J, de Rezende JM, et al. New evidence of spontaneous cure in human Chagas' disease. Rev Soc Bras Med Trop. 2003;36:103-7.
44. Des Jarlais DC, Lyles C, Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94:361-6.
45. Urbina JA. Chemotherapy of Chagas disease. Curr Pharm Des. 2002;8:287-95.
46. Andrade SG, Magalhães JB, Pontes AL. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull World Health Organ. 1985;63:721-6.
47. Sosa-Estani S, Armenti A, Araujo G, Viotti R, Lococo B, Ruiz Vera B, et al. [Treatment of Chagas disease with benznidazole and thioctic acid]. Medicina (B Aires). 2004;64:1-6.